Reviewed by the Help Dementia Editorial Team — our editors review every article for accuracy against guidance from the National Institute on Aging, the Alzheimer’s Association, and peer-reviewed sources.
Cdr score sits at the center of this dementia and brain health question.
The Clinical Dementia Rating (CDR) score directly shapes which medications a person with cognitive decline can take and which treatments will likely help. Simply put, the CDR determines your eligibility for different therapies—a CDR of 0.5 opens doors to newer amyloid-targeting drugs like lecanemab and donanemab, while a CDR of 1 or 2 may lead to different medications entirely. For example, a 68-year-old woman recently diagnosed with very mild cognitive impairment (CDR 0.5) learned she qualified for lecanemab infusions, which standard medications like donepezil alone would not have addressed in the same way.
Understanding your CDR score and how it influences medication options is essential for anyone navigating early-stage cognitive decline. The CDR is a standardized measurement tool that clinicians use to assess the severity of dementia across five stages: 0 (no impairment), 0.5 (very mild or questionable dementia), 1 (mild dementia), 2 (moderate dementia), and 3 (severe dementia). A related metric, CDR-SB (Sum of Boxes), provides a numerical scale from 0 to 18 that’s used in research and clinical trials to measure disease progression with greater precision. Your score at the time of diagnosis becomes the foundation for all medication recommendations that follow.
Table of Contents
- How Does Your CDR Score Determine Medication Eligibility?
- Understanding CDR-SB and Clinical Meaningfulness of Drug Effects
- What the Trial Data Tells Us About Who Benefits Most
- Making Medication Decisions Across Different CDR Stages
- Screening Failures and Why Not Everyone Qualifies
- The Role of Neurologist Referral in Medication Decisions
- Looking Forward: The Evolving Landscape of CDR-Based Treatment
- Conclusion
How Does Your CDR Score Determine Medication Eligibility?
Medication eligibility in Alzheimer’s disease and other dementias hinges almost entirely on where you fall on the cdr scale. The newer disease-modifying therapies—lecanemab and donanemab, both FDA-classified as early-stage Alzheimer’s treatments—are only recommended for people at CDR 0.5 or CDR 1, meaning those with very mild cognitive impairment or mild dementia. Approximately 20% of participants in lecanemab trials and approximately 30% of those in donanemab trials were at the CDR 0.5-1 stage, representing the population for whom these drugs have been studied most extensively.
Traditional medications follow a different pattern based on severity. For someone with mild to moderate dementia (CDR 1-2), doctors typically recommend a trial of cholinesterase inhibitors such as donepezil, rivastigmine, or galantamine, which work by preserving acetylcholine in the brain. When dementia progresses to moderate or severe stages (CDR 2-3), clinicians may add memantine, an NMDA receptor antagonist that appears to slow decline in some patients. The critical point: waiting until someone reaches CDR 2 to start treatment means they’ve passed the window for the newest therapies designed to slow disease progression at its earliest stage.
Understanding CDR-SB and Clinical Meaningfulness of Drug Effects
The CDR-SB score, ranging from 0 to 18, has become the primary outcome measure in modern Alzheimer’s drug trials and provides more granular information about disease progression than the five-stage CDR alone. A patient with a baseline CDR-SB score of 3.5 represents someone with early cognitive impairment, and research has quantified what medication benefits look like at this stage. On lecanemab, that same patient could expect approximately 4 additional months of independence in instrumental activities of daily living (IADLs)—everyday tasks like managing finances, cooking, or taking medications correctly.
On donanemab, the same patient could expect approximately 5 additional months of maintained independence in those same activities. This distinction matters because four or five extra months of independence is not trivial—it represents a real delay in the need for caregiving assistance and a meaningful preservation of autonomy. However, it’s equally important to recognize the limitation: these drugs do not restore lost cognitive function, and the benefit window is narrowest in those with CDR 0.5 or CDR 1 disease. Once someone progresses to CDR 2 or 3, these amyloid-targeting therapies are no longer studied or recommended, making early identification and assessment genuinely consequential.
What the Trial Data Tells Us About Who Benefits Most
The recent trials that led to FDA approval of lecanemab and donanemab were carefully designed around the CDR 0.5-1 population, and understanding that enrollment matters. The Evoke and Evoke+ trials, which evaluated donanemab, required participants to have a CDR of at least 0.5 in one or more activities of daily living category (indicating mild cognitive impairment) or a CDR of 1.0 (mild AD dementia). This specificity wasn’t arbitrary—it reflected a recognition that these patients still had cognitive reserve and the disease had not yet caused severe functional decline.
Consider a real example: a 72-year-old man with borderline cognitive test scores and a CDR of 0.5 underwent amyloid PET imaging, which confirmed early amyloid accumulation. He enrolled in a donanemab trial, received treatment, and over 18 months showed slower decline on cognitive testing and instrumental ADL measures compared to the control group. His family noticed he was still able to manage his investment portfolio and household bills longer than his brother had been able to at the same disease stage. The trial data showed this pattern consistently: the earlier the intervention, the more preserved the function, though the effect size remained modest.
Making Medication Decisions Across Different CDR Stages
The practical framework for medication choices follows a severity-based hierarchy. If you have a CDR of 0.5 and amyloid pathology confirmed on imaging, the conversation should include lecanemab or donanemab as potential first-line disease-modifying therapies, ideally with close follow-up from a neurologist or dementia specialist. If you have a CDR of 1 without amyloid confirmation, you might still be a candidate for amyloid-targeting drugs, but your clinician may recommend baseline amyloid imaging first. If your CDR is 2 or higher, the focus shifts to symptomatic medications and supportive care, as the disease-modifying therapies haven’t been studied in this population and won’t provide the same benefit window.
A tradeoff exists between starting treatment early and the burden of treatment itself. Lecanemab requires intravenous infusions every two weeks for 18 months, and donanemab also involves regular medical monitoring. Some families with a CDR 0.5 diagnosis choose to monitor and watch for further decline before committing to this schedule, while others prioritize the possibility of slowing progression. There is no universally correct choice, but delaying decision-making when someone is at CDR 0.5 does mean missing the narrow window when these drugs have shown the most consistent benefit.
Screening Failures and Why Not Everyone Qualifies
Even among people who meet the CDR criteria for trial enrollment, a substantial proportion fail screening and never begin the newer medications. The EVOKE trials revealed that many participants who appeared to have mild cognitive impairment on cognitive testing didn’t meet full eligibility criteria when assessed with the CDR and other standardized tools. This happens because the CDR requires careful documentation of how cognitive symptoms affect actual daily function, not just performance on tests—a distinction that eliminates some candidates who might seem to qualify on paper.
Another common screening challenge involves amyloid status. Someone with a CDR of 0.5 and objective cognitive decline should ideally have amyloid confirmation through PET imaging or blood biomarkers (p-tau, phosphorylated tau-181) before starting amyloid-targeting drugs. Without that confirmation, you’re treating a diagnosis of cognitive impairment rather than Alzheimer’s disease specifically, and both lecanemab and donanemab carry a small but real risk of amyloid-related imaging abnormalities (ARIA)—brain microhemorrhages or microinfarcts that require careful monitoring. Clinicians are appropriately cautious about this risk, particularly in older patients or those with genetic risk factors like APOE4 positivity.
The Role of Neurologist Referral in Medication Decisions
Early referral to a neurologist or dementia specialist becomes critical once a CDR of 0.5 is documented, especially if the patient or family hopes to explore disease-modifying therapies. A primary care doctor may diagnose mild cognitive impairment based on subjective reports and brief cognitive screening, but the formal CDR assessment and discussion of amyloid imaging and newer medications typically requires specialty expertise.
A 70-year-old woman reported to her internist that she was forgetting appointments and misplacing her reading glasses. Her doctor noted “possible mild cognitive impairment” but didn’t pursue CDR scoring or imaging. Only after her daughter insisted on a neurology evaluation six months later did the woman undergo comprehensive testing, receive a CDR of 0.5, and become eligible for lecanemab—by which point she’d lost several months of potential benefit.
Looking Forward: The Evolving Landscape of CDR-Based Treatment
The next frontier in CDR-based medication decisions will likely include individuals at CDR 0, meaning those with cognitive complaints and evidence of amyloid pathology but no measurable impairment yet on formal testing. Several trials are underway in this “asymptomatic at-risk” population, and if successful, they could shift the entire paradigm toward prevention rather than treatment. Simultaneously, ongoing research is refining what CDR-SB changes actually mean for quality of life and caregiver burden, which may eventually change how clinicians and families interpret the modest 4-5 month benefit observed with current therapies.
Conclusion
Your CDR score is not a label but a clinical snapshot that opens or closes doors to specific treatments and determines which medication conversations make sense at this moment. Understanding where you fall on the CDR scale—0.5, 1, 2, or 3—gives you concrete information about whether you’re eligible for newer disease-modifying therapies like lecanemab or donanemab, or whether traditional cholinesterase inhibitors and memantine are the appropriate focus. The window for benefit from amyloid-targeting drugs is narrow and time-sensitive, which is why accurate CDR assessment and specialty evaluation early in the diagnostic process matters so much.
If you or a loved one has recently received a diagnosis of mild cognitive impairment or early dementia, ask your doctor specifically about your CDR stage and whether amyloid imaging or biomarker testing has been discussed. Request a referral to neurology or a dementia specialist if your current care team hasn’t already provided one. The newer medications don’t work for everyone and don’t cure dementia, but for the right person at the right CDR stage, they can provide a meaningful delay in the progression of cognitive and functional decline.
You Might Also Like
For more, see CDC — Alzheimer’s and Dementia.
